Josh D Woolley1, Baber K Khan, Alamelu Natesan, Anna Karydas, Mary Dallman, Peter Havel, Bruce L Miller, Katherine P Rankin. 1. From the Departments of Psychiatry (J.D.W.), Physiology (M.D.), and Neuroscience (M.D.), and Department of Neurology, Memory and Aging Center (B.K.K., A.N., A.K., B.L.M., K.P.R.), University of California, San Francisco; Department of Psychiatry (J.D.W.), San Francisco Veterans Affairs Medical Center; and Departments of Molecular Biosciences and Nutrition (P.H.), School of Veterinary Medicine, University of California, Davis.
Abstract
OBJECTIVE: To investigate whether patients with behavioral variant frontotemporal dementia (bvFTD) have dysregulation in satiety-related hormonal signaling using a laboratory-based case-control study. METHODS: Fifty-four participants (19 patients with bvFTD, 17 patients with Alzheimer disease dementia, and 18 healthy normal controls [NCs]) were recruited from a tertiary-care dementia clinic. During a standardized breakfast, blood was drawn before, during, and after the breakfast protocol to quantify levels of peripheral satiety-related hormones (ghrelin, cortisol, insulin, leptin, and peptide YY) and glucose. To further explore the role of patients' feeding abnormalities on hormone levels, patients were classified into overeating and nonovereating subgroups based on feeding behavior during separate laboratory-based standardized lunch feeding sessions. RESULTS: Irrespective of their feeding behavior in the laboratory, patients with bvFTD, but not patients with Alzheimer disease dementia, have significantly lower levels of ghrelin and cortisol and higher levels of insulin compared with NCs. Furthermore, while laboratory feeding behavior did not predict alterations in levels of ghrelin, cortisol, and insulin, only patients with bvFTD who significantly overate in the laboratory demonstrated significantly higher levels of leptin compared with NCs, suggesting that leptin may be sensitive to particularly severe feeding abnormalities in bvFTD. CONCLUSIONS: Despite a tendency to overeat, patients with bvFTD have a hormonal profile that should decrease food intake. Aberrant hormone levels may represent a compensatory response to the behavioral or neuroanatomical abnormalities of bvFTD.
OBJECTIVE: To investigate whether patients with behavioral variant frontotemporal dementia (bvFTD) have dysregulation in satiety-related hormonal signaling using a laboratory-based case-control study. METHODS: Fifty-four participants (19 patients with bvFTD, 17 patients with Alzheimer disease dementia, and 18 healthy normal controls [NCs]) were recruited from a tertiary-care dementia clinic. During a standardized breakfast, blood was drawn before, during, and after the breakfast protocol to quantify levels of peripheral satiety-related hormones (ghrelin, cortisol, insulin, leptin, and peptide YY) and glucose. To further explore the role of patients' feeding abnormalities on hormone levels, patients were classified into overeating and nonovereating subgroups based on feeding behavior during separate laboratory-based standardized lunch feeding sessions. RESULTS: Irrespective of their feeding behavior in the laboratory, patients with bvFTD, but not patients with Alzheimer disease dementia, have significantly lower levels of ghrelin and cortisol and higher levels of insulin compared with NCs. Furthermore, while laboratory feeding behavior did not predict alterations in levels of ghrelin, cortisol, and insulin, only patients with bvFTD who significantly overate in the laboratory demonstrated significantly higher levels of leptin compared with NCs, suggesting that leptin may be sensitive to particularly severe feeding abnormalities in bvFTD. CONCLUSIONS: Despite a tendency to overeat, patients with bvFTD have a hormonal profile that should decrease food intake. Aberrant hormone levels may represent a compensatory response to the behavioral or neuroanatomical abnormalities of bvFTD.
Authors: H J Rosen; M L Gorno-Tempini; W P Goldman; R J Perry; N Schuff; M Weiner; R Feiwell; J H Kramer; B L Miller Journal: Neurology Date: 2002-01-22 Impact factor: 9.910
Authors: B Otto; U Cuntz; E Fruehauf; R Wawarta; C Folwaczny; R L Riepl; M L Heiman; P Lehnert; M Fichter; M Tschöp Journal: Eur J Endocrinol Date: 2001-11 Impact factor: 6.664
Authors: Frank Tacke; Georg Brabant; Elmar Kruck; Rüdiger Horn; Patrick Schöffski; Hartmut Hecker; Michael P Manns; Christian Trautwein Journal: J Hepatol Date: 2003-04 Impact factor: 25.083
Authors: David E Cummings; David S Weigle; R Scott Frayo; Patricia A Breen; Marina K Ma; E Patchen Dellinger; Jonathan Q Purnell Journal: N Engl J Med Date: 2002-05-23 Impact factor: 91.245
Authors: Rebekah M Ahmed; Sahar Latheef; Lauren Bartley; Muireann Irish; Glenda M Halliday; Matthew C Kiernan; John R Hodges; Olivier Piguet Journal: Neurology Date: 2015-09-16 Impact factor: 9.910
Authors: Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan Journal: Nat Rev Neurol Date: 2018-03-23 Impact factor: 42.937
Authors: Phillip D Fletcher; Laura E Downey; Hannah L Golden; Camilla N Clark; Catherine F Slattery; Ross W Paterson; Jonathan D Rohrer; Jonathan M Schott; Martin N Rossor; Jason D Warren Journal: Brain Date: 2015-10-12 Impact factor: 13.501
Authors: Alexandra E Thompson; Camilla N Clark; Christopher J Hardy; Phillip D Fletcher; John Greene; Jonathan D Rohrer; Jason D Warren Journal: Neurocase Date: 2016-03-10 Impact factor: 0.881